Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00638456 |
Recruitment Status :
Completed
First Posted : March 19, 2008
Results First Posted : August 14, 2019
Last Update Posted : August 14, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Eosinophilic Esophagitis | Drug: Budesonide plus Prevacid Drug: placebo plus Prevacid | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial |
Study Start Date : | February 2008 |
Actual Primary Completion Date : | September 2009 |
Actual Study Completion Date : | September 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
oral viscous budesonide plus Prevacid
|
Drug: Budesonide plus Prevacid
Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months. |
Placebo Comparator: 2
placebo plus Prevacid
|
Drug: placebo plus Prevacid
Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months. |
- Number of Participants With Improvement of Espohageal Eosinophilia [ Time Frame: 3 Months ]Repeat endoscopy was undertaken using the Olympus P160 endoscope (by RD) at 3 months of treatment.
- Upper Gastrointestinal Endoscopy Score [ Time Frame: Baseline and 3 Months ]
Endoscopy scoring tool took into account the following categories:
Mucosal pallor/reduced vasculature Linear furrows/mucosal thickening White plaques Concentric rings/stricture Friability/"tissue-paper" mucosa Histology scoring tools Epithelial histology score Peak eosinophil count
Each category could score 0-3 for a total maximum score of 15. The higher the score the worse the disease.
- Symptom Score [ Time Frame: Baseline and 3 Months ]
Total score was based on the following symptoms:
Heartburn/regurgitation Abdominal pain Nausea/vomiting Anorexia/early satiety Dysphagia Symptom induced nocturnal wakening Gastrointestinal bleeding
Each symptom could score 0-2 for a maximum score for 14 points. The lower the score the milder the symptoms and the higher the score the more severe symptoms.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologic evidence of EE defined as greater than 20 eosinophils per hpf on esophageal biopsy
- Ages 1 yrs and older
- Ability to continue the same diet that the patient was on at the time of EGD with biopsy
Exclusion Criteria:
- Adverse reaction or allergy to budesonide
- Pregnancy
- Chronic diseases requiring immunomodulatory therapy
- Use of swallowed topical corticosteroids for EE within the past 3 months
- Use of systemic steroids 2 months prior to study entry
- Upper gastrointestinal bleed within 4 months of study entry
- Chronic use of medications that predispose to upper gastrointestinal bleeding including non-steroidal anti-inflammatory medications or anticoagulants
- Evidence of adrenal suppression prior to study entry
- Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis
- Recent changes in asthma or allergic rhinitis therapy for 3 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00638456
United States, California | |
Rady Children's Hospital, San Diego | |
San Diego, California, United States, 92123 |
Principal Investigator: | Ranjan Dohil, MD | UCSD |
Responsible Party: | Ranjan Dohil, Professor, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00638456 |
Other Study ID Numbers: |
VPI-106-01 |
First Posted: | March 19, 2008 Key Record Dates |
Results First Posted: | August 14, 2019 |
Last Update Posted: | August 14, 2019 |
Last Verified: | July 2019 |
Eosinophils Esophagitis Microscopy |
Eosinophilic Esophagitis Esophagitis Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Eosinophilia Leukocyte Disorders Hematologic Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Budesonide Lansoprazole Dexlansoprazole |
Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Ulcer Agents Gastrointestinal Agents Proton Pump Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |